Nuvectis Pharma Reports Q3 2026 Financial Results and Clinical Pipeline Updates
Nuvectis Pharma (NVCT) transitioned into a late-stage clinical development company during the third quarter, highlighted by the acquisition of ex-China rights for two product candidates from Haisco Pharmaceutical Group. Despite reporting a net loss of $30.1 million due to a $20.0 million upfront licensing payment, the company's adjusted net loss was significantly lower at $5.8 million. The firm maintains a strong liquidity position with $140.7 million in cash and equivalents, providing a projected runway into the second half of 2029. Clinical data updates showed positive results for ciprocopan in hemoglobin response and proteinuria reduction for IgA nephropathy. Additionally, NXP200 demonstrated significant efficacy in Phase 1b studies for glioma patients, achieving an objective response rate of approximately 40-43%. While management remains optimistic about the $20 billion potential market for IgA nephropathy, they noted the possibility that the FDA may require additional clinical trials for ciprocopan in the United States.
Tickers: $NVCT
Topics: biotechnology cash runway clinical trial results earnings report
Read the full article at Motley Fool
Part of the story InMode Reports Q3 2026 Financial Results with Stable Revenue and Reaffirmed Outlook (23 articles)